Clinical trial
Insulin Glulisine in Type 1 Diabetes Mellitus
NCT00297583 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00297583 |
|---|---|
| Title | Insulin Glulisine in Type 1 Diabetes Mellitus |
| Official title | A Single-center, Randomized, Double-blind, 3-period Cross-over Trial to Compare the Effect of Insulin Glulisine, Insulin Lispro and Unmodified Human Insulin on the Endogenous Glucose Production in Type 1 Diabetic Patients. |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Type 1 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Insulin Glulisine |
| Start date | Apr 1, 2004 |
| Primary completion | May 1, 2004 |
| First posted | Feb 28, 2006 |
| Last update posted | Dec 7, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: